Invatec Set to Dominate Stage at EuroPCR with its new IN.PACT Line of Drug Eluting Balloons

The only company with a Drug-Eluting Balloon available on Three Different
Platforms
BARCELONA, Spain--(Business Wire)--
Invatec, a comprehensive innovator of interventional products, today announced
the impressive product line-up it will display at the EuroPCR Congress in
Barcelona this week. The company will demonstrate its full range of
interventional cardiology and peripheral vascular products for the treatment of
coronary and peripheral arterial disease, with particular focus on its newly
CE-marked family of IN.PACT paclitaxel-eluting balloon catheters.

With the just announced launch of the IN.PACT Falcon for the Coronary arteries
and the CE Mark and launch of the IN.PACT Admiral for the Superficial Femoral
Artery (SFA) in the thigh, together with the previously launched IN.PACT
Amphirion for Below the Knee (BtK), Invatec has become the only manufacturer in
the world offering a Drug Eluting Balloon on three different product platforms.

"There has been a huge amount of investment in the area of drug-eluting devices
over the last few years," commented Andrea Venturelli and Stefan Widensohler,
co-founders of Invatec. "The advances that have been made in interventional
medicine in the last 10 years have been tremendous and it will be fascinating to
see some of the new developments that will be on display and up for discussion
at this year`s PCR Congress, including our own IN.PACT product line,
representing a new and sustainable platform for the treatment of Coronary Artery
Disease (CAD) and Peripheral Artery Disease (PAD). Going forward we plan to
invest heavily into clinical research programs that will further confirm the
clinical effectiveness of the IN.PACT technology platform and expand the
clinical indications for its use worldwide. "

The Invatec IN.PACT technology platform features FreePac, a proprietary coating
that frees and separates paclitaxel molecules and facilitates their absorption
into the wall of the artery. The FreePac coating was developed in close
collaboration with the researchers who pioneered drug-eluting balloon therapy,
Ulrich Speck, Ph.D., Department of Radiology at Charite Mitte, Berlin and Bruno
Scheller, M.D., University Hospital, Department of Internal Medicine,
Homburg/Saar.

# # # #

About Invatec

Headquartered in Italy and with manufacturing in Italy and Switzerland, Invatec
is one of the world`s fastest growing companies in the design, development and
production of interventional cardiology and peripheral vascular products for the
treatment of coronary and peripheral arterial disease. Driven by research and
technology, Invatec actively collaborates with physicians and centres of
excellence to develop products that will improve life expectancy and quality of
life for patients. Vertically integrated, Invatec also has the in-house ability
to design, develop, manufacture and assemble its entire product offering from
raw materials. As a result, the company has one of the largest therapeutic
catheter product lines in the world, including 9 stent platforms, 6 angioplasty
balloon platforms, 3 drug-eluting balloon platforms and accessory devices, now
sold in over 70 countries.

Dedicated to "making ideas come alive," the company was founded in 1996 by
Andrea Venturelli and Stefan Widensohler, and has grown to almost 1,000
employees. For more information, visit www.invatec.com.

Schwartz Communications
Victoria Harvey
T: + 44 (0) 7534 906616
E: invateceu@schwartz-pr.com
or
Invatec
Rick Geoffrion
T: + 41 (0) 7 96 79 88 99
E: rick.geoffrion@invatec.com

Copyright Business Wire 2009